Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Maxim Group Emerging Growth Virtual Conference 2021
15 slides from Nemaura Medical's conference presentation, Mar 15, 2021
Slide 1: Corporate Presentation - Maxim Group Emerging Growth Virtual Conference
Corporate Presentation Maxim Group Emerging Growth Virtual Conference Dr Faz Chowdhury, CEO M arch 17 - 18, 2021
Slide 2: Forward-Looking Statements
Forward - Looking Statements • This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms
Slide 3: Obesity and Diabetes: Two major drivers of the chronic disease epidemic
Obesity and Diabetes: TWO of the major drivers of the chronic disease Epidemic The added cost of managing a Type 2 diabetic person is >$6000/year. This can be avoided by preventing or reversing Type 2 Diabetes 3 Pre - Diabetics >80 million Type 2 >25 million
Slide 4: Key Targets
Key Targets 1. Prevent diabetes in >80 million people with pre - diabetes in the USA 1. Reverse Diabetes in >25 million persons in the USA 4
Slide 5: Our Solution
Our Solution A World first daily wear Continuous glucose monitor* Applicable for Pre - diabetes (diabetes prevention), Type 1 (glucose trending) and Type 2 Diabetes (glucose trending and diabetes reversal) Total addressable market exceeding $ 150 Billion 1,2,3 CE approved Class 2b Medical device – a
Slide 6: Why we are different
Why we are different A World first daily wear Continuous glucose monitor – currently no other sensor technology like it (to best of our knowledge)* Highly competitive pricing allowing broader adoption to address unmet clinical needs Allows us to target the Medical market and consumer market with a d
Slide 7: How it works
How it works Apply the sensor
Slide 8: How it works
How it works @ See changes as they happen Helps you understand your unique glucose trend line and lifestyle choices taken.
Slide 9: How it works
How it works YesYouCan BEAT™diabetes
Slide 10: Benefits over HbA1c
Benefits over HbA1c Thesame HbAlc presented differently
Slide 11: BEAT diabetes program full launch December 2020 in USA
11 FULL PROGRAM LAUNCHED DECEMBER 2020 IN USA 3 CORE COMPONENTS 1. Weight loss program originally developed at the Joslin Diabetes Centre – over 12 years of clinical evidence. Sustained long term weight loss achieved without loss of muscle mass 2. proBEAT Ρ glucose profiling – using world’s first da
Slide 12: Intermittent Glucose Profiling: Benefits
Intermittent Glucose Profiling: B enefits 12 7 - point glucose profiles every 4 weeks. Patients received guidance for diet and exercise adjustments based on SMBG. Outcome: Significant reductions in HbA1c, weight, BMI, systolic BP, diastolic BP, and LDL Cholesterol Kempf et. al., Diabetes Technol The
Slide 13: Glucose trend and individual metabolic health
13 Glucose trend and diet , exercise , and other parameters used to determine individual metabolic health . Combine with education and guidance
Slide 14: Key Milestones for 2021
14 KEY MILESTONES FOR 2021 1. Adoption of BEATdiabetes program by several large corporations/employers and Insurers in the USA (initially) 2. Launch of consumer device and program addressing Metabolic health and weight loss through glucose control 3. Launch sugarBEAT real time non - invasive continu
Slide 15: Summary
SUMMARY 1. Total addressable market >$150 Billion 2. World’s first daily wearable sensor with unparalleled economics 3. Targeting prevention and/or reversal of Type 2 diabetes with significant long term savings 4. Glucose profiling a few days a month provides a powerful cost - effective tool to faci
Nemaura Medical — Maxim Group Emerging Growth Virtual Conference 2021 on 6ix